Financial Instruments and Fair Value Measurements (Narrative) (Details) CAD in Millions, $ in Millions	12 Months Ended
	Sep. 25, 2015 USD ($) supplier reactor	Sep. 25, 2015 CAD supplier reactor	Sep. 25, 2015 CAD	Sep. 26, 2014 USD ($)	Aug. 31, 2014 USD ($)	Aug. 14, 2014 USD ($)	Apr. 30, 2013	Oct. 01, 2012 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of Suppliers of Unique Raw Material | supplier	8	8
Number of Nuclear Research Reactors Used To Source Raw Material | reactor	3	3
Number of Nuclear Reactors Relied on For Supply of Raw Material | reactor	2	2
Novartis 2015 and 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Annual Payments	$ 25.0
Novartis, Subsequent to 2016 till FDA Approval
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Annual Payments	25.0
Novartis, Subsequent to FDA Approval
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Potential Payment	$ 25.0
CNS Therapeutics, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition								$ 6.9
Maximum contingent payments for acquisition								$ 9.0
Discount rate	1.00%	1.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability	$ 7.2
Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition						$ 0.0
Maximum contingent payments for acquisition	$ 190.0
Discount rate	4.70%	4.70%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability	$ 167.4				$ 195.4
Questcor Pharmaceuticals, Inc. | BioVectra Financial Results
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	1.30%	1.30%
2.85% term loan due April 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	2.85%	2.85%
4.00% term loan due February 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	4.00%	4.00%
Debentures | 8.00% debentures due March 2023 | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	8.00%		8.00%
Debentures | 9.50% debentures due May 2022 | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	9.50%		9.50%
Senior Notes | 3.50% notes due April 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate							3.50%
Senior Notes | 3.50% notes due April 2018 | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	3.50%		3.50%
Senior Notes | 4.75% notes due April 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate							4.75%
Senior Notes | 4.75% notes due April 2023 | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	4.75%		4.75%
Senior Notes | 5.75% notes due August 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	5.75%	5.75%
Stated interest rate					5.75%
Debentures | Four Point Eight Eight Percent Notes [Member] | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	4.875%		4.875%
Debentures | Five Point Five Percent Notes [Member] | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	5.50%		5.50%
Debentures | 5.625% notes due October 2023 | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	5.625%		5.625%
Carrying Value | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	$ 66.3			$ 69.8
Carrying Value | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash surrender value of life insurance	67.7			$ 67.3
BioVectra Inc [Member] | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition | CAD			CAD 50.0
Business Combination, Contingent Consideration, Potential Payment | CAD			CAD 40.0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements | CAD		CAD 5.0
Synacthen [Member] | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Milestone Payments	$ 25.0